NCT05659056 2024-04-16Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast CancerThe First Affiliated Hospital with Nanjing Medical UniversityPhase 2 Recruiting65 enrolled